secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056977
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics Q1 net loss $66.9M; paltusotine NDA on track for 2H 2024
------------------------------------------------------------------

- Net loss of $66.9M in Q1 2024 vs $46.0M in Q1 2023; revenue fell to $0.6M from $2.7M.
- Cash, equivalents, and investments total $901.0M as of March 31, 2024, partly from $350M private placement in Feb.
- Paltusotine PATHFNDR-2 Phase 3 met primary and all secondary endpoints; NDA submission expected in 2H 2024.
- Initial atumelnant Phase 2 results in CAH and Cushing's to be presented at ENDO 2024 (June 1-4).
- Plan to initiate paltusotine Phase 3 in carcinoid syndrome by end of 2024 pending FDA discussions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024056977/0000950170-24-056977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024056977/crnx-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer